Clinical Trial: The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women With Female Sexual Arousal Disorder.
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Phase 2a Multi-Centre, Double Blind, Placebo Controlled Cross-Over Trial To Investigate The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women Diagnosed With Female Sexual Arousal
Brief Summary: CP-866,087 is a non-hormonal compound, acting on the central nervous system, which has been shown in animal models to restore sexual function.
Detailed Summary:
Sponsor: Pfizer
Current Primary Outcome:
- Diary events, including Satisfactory Sexual Experiences (SSEs) over 6 weeks. [ Time Frame: 6 weeks ]
- Score in Abbreviated Sexual Function Questionnaire after 6 weeks of treatment. [ Time Frame: 6 weeks ]
Original Primary Outcome: Score in Abbreviated Sexual Function Questionnaire after 6 weeks of treatment. Diary events, including Satisfactory Sexual Experiences (SSEs) over 6 weeks.
Current Secondary Outcome:
- Exit interview at end of study. Meaningful Benefit Question at end of study. [ Time Frame: End of study ]
- Measure of Female Sexual Distress questionnaire after 6 weeks of treatment. [ Time Frame: 6 weeks ]
Original Secondary Outcome:
- Measure of Female Sexual Distress questionnaire after 6 weeks of treatment.
- Exit interview at end of study. Meaningful Benefit Question at end of study.
Information By: Pfizer
Dates:
Date Received: June 1, 2007
Date Started: July 2007
Date Completion:
Last Updated: October 27, 2010
Last Verified: October 2010
